DEVICE CIVIL PENALTIES CAN BE IMPOSED WITHOUT ISSUANCE OF FINAL RULE, FDA SAYS IN RESPONSE TO LAWSUIT; AGENCY HAS "NO PLANS" TO PUBLISH PMS REG
This article was originally published in The Gray Sheet
Executive Summary
Existing FDA procedures for device civil penalties allow FDA to enforce the provision of the Safe Medical Devices Act of 1990 without publishing a final rule, the agency argues in response to a lawsuit brought by Public Citizen. In the Oct. 28, 1994 complaint, Public Citizen argued that FDA's failure to finalize civil penalty rules and three other regulations constitutes an "unreasonable delay" under the Administrative Procedures Act and asked the court to order the agency to publish the regs ("The Gray Sheet" Oct. 31, 1994, p. 18).
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.